Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T3P-Y058-739
- Development stage
- Phase 2
- Lead developer
- T3 Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
T3P-Y058-739 is a genetically modified, live attenuated strain of the bacterium *Yersinia enterocolitica* developed as an experimental cancer therapy. It utilizes a proprietary platform based on the bacterial type III secretion (T3S) system, which acts as a nano-syringe to inject bioactive protein payloads directly into tumor cells. Upon administration, these bacteria selectively colonize solid tumors and deliver proteins that activate type I interferon (IFN) and Toll-like receptor (TLR)-mediated signaling pathways. This mechanism stimulates the immune system to recognize and attack cancer cells by inducing a highly specific anti-tumor immune response while minimizing effects on healthy tissue. The drug is currently being evaluated in phase 1/2 clinical trials for advanced malignant solid neoplasms, both as monotherapy and in combination with pembrolizumab[1][2][4][5][6][7].
- Other names
- bacterial type III secretion-based agent T3P-Y058-739
02
Targets
TLR (Toll-like receptors)
Beyond the preview
Go deeper on T3P-Y058-739.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T3P-Y058-739.